Abstract:Asthma is a heterogeneous inflammatory disease of the airways that is associated with airway hyperresponsiveness and airflow limitation. Although asthma was once simply categorized as atopic or nonatopic, emerging analyses over the last few decades have revealed a variety of asthma endotypes that are attributed to numerous pathophysiological mechanisms. The classification of asthma by endotype is primarily routed in different profiles of airway inflammation that contribute to bronchoconstriction. Many asthma therapeutics target G protein-coupled receptors (GPCRs), which either enhance bronchodilation or prevent bronchoconstriction. Short-acting and long-acting β 2-agonists are widely used bronchodilators that signal through the activation of the β 2-adrenergic receptor. Short-acting and long-acting antagonists of muscarinic acetylcholine receptors are used to reduce bronchoconstriction by blocking the action of acetylcholine. Leukotriene antagonists that block the signaling of cysteinyl leukotriene receptor 1 are used as an add-on therapy to reduce bronchoconstriction and inflammation induced by cysteinyl leukotrienes. A number of GPCR-targeting asthma drug candidates are also in different stages of development. Among them, antagonists of prostaglandin D2 receptor 2 have advanced into phase III clinical trials. Others, including antagonists of the adenosine A2B receptor and the histamine H4 receptor, are in early stages of clinical investigation. In the past decade, significant research advancements in pharmacology, cell biology, structural biology, and molecular physiology have greatly deepened our understanding of the therapeutic roles of GPCRs in asthma and drug action on these GPCRs. This review summarizes our current understanding of GPCR signaling and pharmacology in the context of asthma treatment. SIGNIFICANCE STATEMENT: Although current treatment methods for asthma are effective for a majority of asthma patients, there are still a large number of patients with poorly controlled asthma who may experience asthma exacerbations. This review summarizes current asthma treatment methods and our understanding of signaling and pharmacology of G protein-coupled receptors (GPCRs) in asthma therapy, and discusses controversies regarding the use of GPCR drugs and new opportunities in developing GPCR-targeting therapeutics for the treatment of asthma.

RhoA/Rho-kinases in Asthma: from Pathogenesis to Therapeutic Targets

Rho-Kinase Inhibition of Active Force and Passive Tension in Airway Smooth Muscle: A Strategy for Treating Airway Hyperresponsiveness in Asthma

Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models

Rho-kinase Inhibitor Attenuates Airway Mucus Hypersecretion and Inflammation Partly by Downregulation of IL-13 and the JNK1/2-AP1 Signaling Pathway.

Reasearch Progress on the Role of Neutrophils in Asthma

Epidermal growth factor receptor in asthma: A promising therapeutic target?

The Function of RhoA/ROCK Pathway and MYOCD in Airway Remodeling in Asthma

IL-1β: a Key Modulator in Asthmatic Airway Smooth Muscle Hyper-Reactivity

Latrophilin Receptors: Novel Bronchodilator Targets in Asthma

Dysregulated retinoic acid signaling in airway smooth muscle cells in asthma

Targeting cell signaling in allergic asthma

Eicosanoid receptors as therapeutic targets for asthma

G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action

Type II alveolar epithelial cell–specific loss of RhoA exacerbates allergic airway inflammation through SLC26A4

Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach

Cytokine targets in airway inflammation

Type Ii Epithelial Rhoa Protects Against Allergic Airway Inflammation And The Formation Of Inducible Bronchus-Associated Lymphoid Tissue (Ibalt)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies

IL-1 beta: a key modulator in asthmatic airway smooth muscle hyper-reactivity

Sigma-1 Receptor Alleviates Airway Inflammation and Airway Remodeling Through AMPK/CXCR4 Signal Pathway

Role of Th17 Cytokines in Airway Remodeling in Asthma and Therapy Perspectives